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Abstract 
Objective To evaluate the effects of intravenous maropitant on arterial blood pressure in healthy dogs 
while awake and under general anesthesia. 
Design Experimental crossover study. 
Animals Eight healthy adult Beagle dogs. 
Procedure All dogs received maropitant (1 mg kg-1) intravenously under the following conditions: 1) 
awake with non-invasive blood pressure monitoring (AwNIBP), 2) awake with invasive blood pressure 
monitoring (AwIBP), 3) premedication with acepromazine (0.005 mg kg-1) and butorphanol (0.2 mg kg-1) 
intramuscularly followed by propofol induction and isoflurane anesthesia (GaAB), and 4) premedication 
with dexmedetomidine (0.005 mg kg-1) and butorphanol (0.2 mg kg-1) intramuscularly followed by 
propofol induction and isoflurane anesthesia (GaDB). Heart rate (HR), systolic (SAP), diastolic (DAP), and 
mean blood pressures (MAP) were recorded before injection of maropitant (baseline), during the first 60 
seconds of injection, during the second 60 seconds of injection, at the completion of injection and every 2 
minutes post injection for 18 minutes. The data were compared over time using a Generalized Linear 
Model with mixed effects and then with simple effect comparison with Bonferroni adjustments (p <0.05). 
Results There were significant decreases from baseline in SAP in the GaAB group (p < 0.01) and in MAP 
and DAP in the AwIBP and GaAB (p < 0.001) groups during injection. A significant decrease in SAP (p < 
0.05), DAP (p < 0.05), and MAP (p < 0.05) occurred at 16 minutes post injection in GaDB group. There was 
also a significant increase in HR in the AwIBP group (p < 0.01) during injection. Clinically significant 
hypotension occurred in the GaAB group with a mean MAP at 54 ± 6 mmHg during injection. 
Conclusion Intravenous maropitant administration significantly decreases arterial blood pressure during 
inhalant anesthesia. Patients premedicated with acepromazine prior to isoflurane anesthesia may 
develop clinically significant hypotension. 
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Abstract
Objective
To evaluate the effects of intravenous maropitant on arterial blood pressure in healthy dogs




Eight healthy adult Beagle dogs.
Procedure
All dogs received maropitant (1 mg kg-1) intravenously under the following conditions: 1)
awake with non-invasive blood pressure monitoring (AwNIBP), 2) awake with invasive blood
pressure monitoring (AwIBP), 3) premedication with acepromazine (0.005 mg kg-1) and butor-
phanol (0.2 mg kg-1) intramuscularly followed by propofol induction and isoflurane anesthesia
(GaAB), and 4) premedication with dexmedetomidine (0.005 mg kg-1) and butorphanol (0.2 mg
kg-1) intramuscularly followed by propofol induction and isoflurane anesthesia (GaDB). Heart
rate (HR), systolic (SAP), diastolic (DAP), and mean blood pressures (MAP) were recorded
before injection of maropitant (baseline), during the first 60 seconds of injection, during the sec-
ond 60 seconds of injection, at the completion of injection and every 2 minutes post injection
for 18 minutes. The data were compared over time using a Generalized Linear Model with
mixed effects and then with simple effect comparison with Bonferroni adjustments (p <0.05).
Results
There were significant decreases from baseline in SAP in the GaAB group (p < 0.01) and in
MAP and DAP in the AwIBP and GaAB (p < 0.001) groups during injection. A significant
decrease in SAP (p < 0.05), DAP (p < 0.05), and MAP (p < 0.05) occurred at 16 minutes
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post injection in GaDB group. There was also a significant increase in HR in the AwIBP
group (p < 0.01) during injection. Clinically significant hypotension occurred in the GaAB
group with a mean MAP at 54 ± 6 mmHg during injection.
Conclusion
Intravenous maropitant administration significantly decreases arterial blood pressure during
inhalant anesthesia. Patients premedicated with acepromazine prior to isoflurane anesthe-
sia may develop clinically significant hypotension.
Introduction
Maropitant is a neurokinin (NK-1) receptor antagonist that inhibits binding of substance P
(SP) in the chemoreceptor trigger zone (CTZ) and the vomiting center (VC), thereby inhibit-
ing emesis in dogs and cats [1]. NK-1 receptors are found in the central nervous system and
peripheral tissues and are involved in pain transmission, vasodilation, inflammatory response
modulation, and sensory neuronal transmission [1,2].
Maropitant is effective in decreasing opioid and alpha-2 agonist induced vomiting and nau-
sea when administered subcutaneously or orally prior to premedication, thereby decreasing
patient discomfort and risk of peri-anesthetic aspiration pneumonia [2–7]. Dogs receiving
maropitant experience improved quality of anesthetic recovery and shortened time to return
to postoperative feeding, which helps mitigate the negative energy balance associated with
surgery and anesthesia [8]. Maropitant may also have a role in providing adjunct analgesia for
visceral pain as it has been shown to decrease the anesthetic inhalant requirement during ovar-
iohysterectomy in dogs and cats [9–14]. Due to the multiple benefits in anesthetic and surgical
patients, maropitant is frequently incorporated into anesthetic protocols in canine and feline
patients. Peri-anesthetic injectable maropitant is often administered via the subcutaneous (SC)
route. The disadvantages of SC administration include pain on injection and the relatively
long onset of action of one hour for prevention of vomiting and signs of nausea [15]. Intrave-
nous (IV) administration was added to the USA label in 2016 which decreases the time for
onset of action and avoids painful SC injection.
Studies by Boscan et al and Alvillar et al observed a transient decrease in mean arterial
blood pressure for approximately 10 minutes when maropitant was administered IV in healthy
dogs under general anesthesia [14,16]. These studies did not quantify the statistical significance
of the observed changes in mean arterial blood pressure. To the author’s knowledge, there are
no published studies or proprietary literature regarding the effect of IV administration of mar-
opitant on arterial blood pressure in either awake or anesthetized dogs.
The primary goal of this study was to document the effect of IV administration of maropi-
tant on arterial blood pressure in a controlled setting with healthy awake and anesthetized
dogs. The effects of maropitant were evaluated with different premedication drugs (aceproma-
zine, dexmedetomidine, and butorphanol) which are commonly used in clinical veterinary
anesthesia [17]. Acepromazine is an α1-adrenergic receptor antagonist that causes a dose
dependent decrease in mean arterial blood pressure due to vasodilation [18]. Dexmedetomi-
dine is α2-adrenergic receptor agonist that increases systemic arterial blood pressure by α2-
adrenergic receptor-mediated constriction of the vascular smooth muscles of arterial vessels
[18]. Butorphanol is a κagonist-μantagonist opioid that provides sedation and mild analgesia
with minimal cardiovascular effects [19]. We hypothesized that maropitant would cause a
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transient decrease in blood pressure with intravenous administration in heathy awake and
anesthetized dogs.
Materials and methods
This study was approved by the Iowa State University Institutional Animal Care and Use
Committee (protocol number 2-18-8702-K). This study was carried out in accordance with
the recommendations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health, and all efforts were made to minimize patient distress and
suffering.
Eight research spayed female beagles from Iowa State University Laboratory Animal
Resource (ISU LAR) were studied in a crossover design. All dogs were 2 years of age and the
mean body weight was 8.7 ± 0.8 kg. The dogs were assigned an ASA (American Society of
Anesthesiologists) physical status of 1 (healthy, no physical abnormalities) based on physical
examination. Dogs were fasted for 12 hours prior to anesthesia but had free access to water up
until the time of the study. The invasive blood pressure transducer was calibrated against a
mercury manometer prior to the start of each experiment. The dogs underwent 4 treatment
protocols each preceded by a 72 hour washout period: 1) awake with indirect (oscillometric)
blood pressure monitoring, 2) awake with direct blood pressure monitoring, 3) general anes-
thesia with direct blood pressure monitoring after premedication with acepromazine/butor-
phanol, and 4) general anesthesia with direct blood pressure monitoring after premedication
with dexmedetomidine/butorphanol. General anesthesia was induced with propofol and fol-
lowed by isoflurane inhalant anesthesia. Each dog served as its own control.
Awake protocols
In the awake protocol with non-invasive blood pressure monitoring (AwNIBP), blood pres-
sure was measured with an oscillometric blood pressure monitor (Cardell1 9402). Dogs were
placed in right lateral recumbency and allowed 5 minutes acclimation time. Lidocaine (2.5
mg) (Lidocaine 2% injection, VETone1) subcutaneous (SC) was injected at the cephalic cathe-
ter site with an insulin syringe (U-100 Insulin Syringes with Ultra-Fine™ needle, BD1) to pre-
vent discomfort associated with IV catheter placement. A 20-gauge IV catheter (Surflo1,
Terumo1) was placed in the cephalic vein. Maropitant (1 mg kg-1) (Cerenia1, Zoetis1) IV
was administered over 2 minutes using hand injection with a timer. The administration time
was determined according to the manufacturer package insert, which states that maropitant
should be administered intravenously over 1–2 minutes. The blood pressure cuff was sized at
40% of limb circumference and placed on the pelvic limb proximal to the tarsus. Heart rate
(HR) and oscillometric pressure readings of systolic (SAP), diastolic (DAP), and mean arterial
pressure (MAP) were obtained prior to injection (baseline), at completion of injection (Tc),
and every 10 minutes for 20 minutes after injection. Three readings were obtained at each
recording time point and averaged.
In the awake group with invasive blood pressure (AwIBP), dogs were placed in right lateral
recumbency and allowed 5 minutes acclimation time. Lidocaine was injected SC at the
cephalic (2.5 mg) and dorsal pedal (2.5 mg) catheter sites with an insulin syringe (U-100 Insu-
lin Syringes with Ultra-Fine™ needle, BD1). A 20-gauge IV catheter was placed in the cephalic
vein. Then, a 22-gauge catheter was placed in the dorsal pedal artery for invasive blood pres-
sure monitoring (Mindray, Datascope Spectrum1). The dorsal pedal artery arterial catheter
was attached to a low-compliance pressure tubing that connected to an electronic pressure
transducer positioned and zeroed at the level of the sternal manubrium. Maropitant (1 mg kg-1
IV) was administered over 2 minutes using hand injection with a timer. Heart rate, SAP, DAP
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and MAP were recorded before injection (baseline), at the start of injection (T0), during the
first 60 seconds of injection (Ta), during the second 60 seconds of injection (Tb), at completion
of injection (Tc) and every 2 minutes post injection (T-2) for 18 minutes (T-18).
General anesthesia protocols
Dogs were premedicated with acepromazine (0.005 mg kg-1) (Acepromazine injection,
VETone1) and butorphanol (0.2 mg kg-1) (Torbugesic1-SA, Zoetis1) (GaAB group) or dex-
medetomidine (0.005 mg kg-1) (Dexdomitor1, Zoetis1) and butorphanol (0.2 mg kg-1) (Tor-
bugesic1-SA, Zoetis1) (GaDB group) intramuscularly (IM) in the lumbar epaxial muscles.
The premedication drug doses were chosen based on doses commonly used at this institution
for clinical patients undergoing anesthesia. Fifteen minutes after premedication, a 20-gauge IV
cephalic catheter was placed after local block with lidocaine (2.5 mg SC) over the catheter site
with an insulin syringe (U-100 Insulin Syringes with Ultra-Fine™ needle, BD1). Dogs were
induced with propofol (PropoFlo™, Zoetis1) 2–4 mg kg-1 IV at a rate of 1.0 mg kg-1 min-1 until
intubation could be achieved. The dogs were intubated when there was an absence of palpebral
reflex, the eye was rotated ventrally, and a lack of jaw tone was evident. Anesthesia was main-
tained with isoflurane (Isoflurane USP, Akorn) and 100% oxygen; the vaporizer was set at 1.0–
1.3% with an oxygen flow rate of 1L min-1. The dogs were placed in right lateral recumbency.
Lactated Ringer’s (Lactated Ringer’s Injection USP, B. Braun) was administered at 5 ml kg-1
hr-1 IV. After induction, lidocaine (2.5 mg) was injected SC at dorsal pedal catheter site with
an insulin syringe (U-100 Insulin Syringes with Ultra-Fine™ needle, BD1). Arterial catheter
was placed in the dorsal pedal artery using a 22-gauge catheter for invasive blood pressure
monitoring. Electrocardiogram, pulse oximetry, body temperature, invasive blood pressure
(SAP, MAP, DAP), end-tidal carbon dioxide, and fraction of expired isoflurane were moni-
tored continuously (Datascope Spectrum1 and Gas Module 3™, Mindray). The dorsal pedal
arterial catheter was attached to a low-compliance pressure tubing that connected to electronic
pressure transducer positioned and zeroed at the level of the sternal manubrium. Anesthetic
depth was assessed as adequate when there was an absence of palpebral reflex, loss of purpose-
ful movement in response to noxious stimulation (toe pinch) with end-tidal isoflurane concen-
tration (EtISO) of 1.0 ± 0.2%. Hypotension was defined as MAP less than 60 mmHg [20,21]. If
hypotension occurred prior to maropitant administration, a 5 to 15 ml kg-1 fluid bolus of Lac-
tated Ringer’s was administered [22]. If hypotension was accompanied by bradycardia (HR
<70 beats per minutes) [23–25] prior to administration of maropitant, glycopyrrolate (0.005–
0.01 mg kg-1 IV) was administered in conjunction with the fluid bolus. When MAP was main-
tained above 60 mmHg for at least 5 minutes, maropitant (1 mg kg-1) IV was administered
over 2 minutes by hand injection using a timer. Heart rate, SAP, DAP, and MAP were
recorded before maropitant injection (baseline), at the start of injection (T0), during the first
60 seconds of injection (Ta), during the second 60 seconds of injection (Tb), at completion of
the injection (Tc) and every 2 minutes post injection (T-2) for 18 minutes (T-18). Ephedrine
(0.1 mg kg-1 IV) was the planned rescue protocol for dogs in which MAP was < 50 mmHg
for� 5 minutes duration after maropitant injection. All research beagles were returned to ISU
LAR at the completion of the study. Recording of the blood pressure and heart rate values was
performed by a non-blinded observer.
All variables were compared between groups and from baseline within each group. A Gen-
eralized Linear Model with mixed effects was fitted using SAS1 software (version 9.4.; SAS1
inst. Cary, NC). The fixed effects were Method and Time; the random effects were beagles. All
time points were compared to baseline and adjusted using a Bonferroni correction. Differences
were considered statistically significant when p� 0.05. The results were expressed as
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mean ± SD. The sample size was determined using a paired t-test with type I error of 5%,
power of 80%, with an effect size of 1.0 based on a previous maropitant study by Boscan et al
[14].
Results
Blood pressure and heart rate changes associated with maropitant administration in the awake
and anesthetized groups are summarized in Table 1 and Figs 1–4.
There was significant difference in SAP, DAP, and MAP over time (p<0.0001) and
between GaAB, GaDB, and AwIBP (p<0.0001).
In the awake group with invasive blood pressure monitoring (AwIBP), there was a signifi-
cant decrease in MAP from the first 60 seconds of injection (Ta) thru 2 minutes post injection
(T-2), and again at 6 minutes post injection (T-6) thru 18 minutes (T-18) compared to baseline.
A significant decrease in DAP was also observed from the first 60 seconds of injection (Ta) to 2
minutes post injection (T-2), at 8 minutes post injection (T-8), and 12 minutes post injection
(T-12) thru 18 minutes post injection (T-18) compared to baseline.
In the anesthetized dogs, the group premedicated with acepromazine (GaAB) showed a sig-
nificant decrease in SAP during the second minute of injection (Tb) and at the completion (Tc)
of injection compared to baseline. A significant decrease in MAP was observed during injec-
tion of maropitant (Ta–Tc). This group also had a significant decrease in DAP during injection
(Ta–Tc) and at 8 minutes (T-8), 12 minutes (T-12), and 16 (T-16) thru 18 minutes (T-18) post
injection compared to baseline. In the anesthetized dogs premedicated with dexmedetomidine
(GaDB), a significant decrease in SAP, MAP and DAP compared to baseline was only observed
at T-16. A significant decrease in SAP and MAP was also observed at T-18 in the GaDB group.
Clinically significant hypotension (defined as MAP less than 60 mmHg) [20,21] was only
observed in the group premedicated with acepromazine (GaAB). Hypotension occurred dur-
ing injection and immediately post injection with a mean MAP (SD) of 54 ± 6 mmHg during
the second minute of injection (Tb). Prior to injection of maropitant, five of the eight dogs
required a fluid bolus and two of the eight dogs also required treatment with glycopyrrolate IV
to achieve MAP > 60 mmHg in GaAB group. None of the other groups required treatment of
hypotension prior to maropitant administration. No dogs required ephedrine administration
during the study.
The awake dogs (AwIBP) were the only group that experienced a significant change in
heart rate over time compared to baseline. This group had a significant increase in heart rate
during the second minute of injection (Tb) and at the completion of injection (Tc) compared
to baseline, and significant decrease in heart rate from T-14 to T-18 compared to baseline. There
was a significant difference in heart rate between the awake dogs (AwIBP), and the anesthe-
tized dogs (GaAB, GaDB (p<0.0001)) over time. The dogs receiving dexmedetomidine
Table 1. Non-invasive blood pressure values in the awake dogs. Values are expressed as mean ± SD. p�0.05 denotes
statistical significance compared to baseline.
Time SAP (p) MAP (p) DAP (p)
Baseline 160 ± 11 121± 14 99 ± 8
Tc 161 ± 13 (p = 1.0) 115 ± 11 (p = 1.0) 93 ± 8 (p = 0.88)
10 min 159 ± 19 (p = 1.0) 125 ± 17 (p = 1.0) 97 ± 17 (p = 1.0)
20 min 153 ± 16 (p = 0.89) 118 ± 15 (p = 1.0) 92 ± 15 (p = 0.29)
There were no significant changes in blood pressure over time compared to baseline in the awake group in which
blood pressure was measured with non-invasive methods (AwNIBP) (p> 0.05).
https://doi.org/10.1371/journal.pone.0229736.t001
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(GaDB) had significantly lower heart rates compared to the awake dogs (AwIBP) and dogs
receiving acepromazine (GaAB) (p<0.0001) during all time points. Dogs in the awake group
(AwIBP) had significantly lower heart rates compared to dogs receiving acepromazine (GaAB)
(p<0.05) at T-8, T-14, T-16, T-18.
Discussion
This study is the first to evaluate blood pressure and heart rate changes associated with intrave-
nous maropitant administration in awake and anesthetized dogs. Intravenous administration
of injectable maropitant causes a significant decrease in blood pressure during injection and
immediately post injection in awake dogs and in anesthetized dogs premedicated with acepro-
mazine. The change in blood pressure was significant over time in each of the individual
groups.
Dogs that were premedicated with acepromazine and anesthetized with isoflurane exhibited
clinical hypotension even prior to maropitant administration. Five out of eight dogs required
treatment to become normotensive. Published studies have reported that the hypotensive
Fig 1. Systolic blood pressure (SAP) of the awake dogs with invasive blood pressure monitoring (AwIBP) and the anesthetized dogs premedicated
with acepromazine (GaAB) or dexmedetomidine (GaDB). Values are expressed as mean ± SD. � Denotes value within a treatment group that differs
significantly (p�0.05) from baseline.
https://doi.org/10.1371/journal.pone.0229736.g001
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effects of acepromazine are enhanced by the decrease in systemic vascular resistance associated
with isoflurane [18,26]. In the present study, hypotension caused by acepromazine and isoflur-
ane was treated with crystalloid fluid boluses. Hypotension caused by absolute hypovolemia,
such as dehydration or hemorrhage, is usually responsive to fluid therapy [27,28]. However,
hypotension that is caused by vasodilation (relative hypovolemia) from anesthetic drugs has
an unpredictable responsiveness to fluid therapy [29,30]. A fluid challenge with crystalloid flu-
ids is recommended in an effort to assess fluid responsiveness in hypotensive dogs under gen-
eral anesthesia [28,31–33]. For this study, fluid treatment for hypotension followed the
American Animal Hospital Association (AAHA) Guidelines for fluid therapy for dogs and cats
[22]. Hypotension that occurred with concurrent bradycardia was treated with glycopyrrolate.
All dogs were able to maintain normotension for 5 minutes prior to maropitant
administration.
Clinically significant arterial hypotension was observed without a significant compensatory
increase in heart rate during maropitant injection in the acepromazine group. Conversely, the
awake group had a significant increase in HR during the period of lower MAP and DAP
Fig 2. Diastolic blood pressure (DAP) of groups AwIBP, GaAB and GaDB. Values are expressed as mean ± SD. � Denotes value within a treatment
group that differs significantly (p�0.05) from baseline.
https://doi.org/10.1371/journal.pone.0229736.g002
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associated with maropitant injection. Inhibition of sympathetic activity, adrenergic neuro-
transmission, and baroreceptor reflex sensitivity by the inhalant and phenothiazine, are possi-
ble factors that contributed to a depressed compensatory response to hypotension during
maropitant injection [28]. Persistent blood pressure reduction that required treatment with
ephedrine was documented in a study that evaluated the antinociceptive effects of maropitant
(5.0 mg kg-1 IV) in cats receiving an IV bolus of maropitant with morphine and acepromazine
as premedication [13]. Our study used the lower label dose of maropitant (1 mg kg-1) which
resulted in transient hypotension with a return to normotension without requiring rescue
blood pressure treatment with ephedrine. Intravenous administration of maropitant may have
a dose dependent response on blood pressure and/or potential species differences in the sever-
ity of blood pressure effects.
The dexmedetomidine group did not experience a significant decrease in blood pressure
associated with maropitant injection. Dexmedetomidine is an α2-receptor agonist that pro-
duces a biphasic hemodynamic response. Activation of subtype α2B-receptorsin the vascular
smooth muscle leads to vasoconstriction and decreased heart rate (phase 1). As dexmedetomi-
dine plasma concentration decreases, vasodilation occurs due to α2A-receptor activation in
vascular endothelium and central effects from decreased norepinephrine release [34,35]. In
dogs, decreased blood pressure during phase 2 is associated with bradycardia from central
Fig 3. Mean arterial blood pressure (MAP) of groups AwIBP, GaAB and GaDB. Values are expressed as mean ± SD. � Denotes value within a
treatment group that differs significantly (p�0.05) from baseline.
https://doi.org/10.1371/journal.pone.0229736.g003
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sympatholytic effects with peripheral effects of α2-agonist subsiding [36,37]. The duration of
effect of dexmedetomidine is approximately 1 hour or less depending on dose [37]. The time
from premedication to the time prior to maropitant injection was approximately 30 to 40
minutes in this study. The decrease in blood pressure in the dexmedetomidine group that was
observed at 16 to 18 minutes post injection may be due to the sympatholytic effect of the dex-
medetomidine and not necessarily associated with maropitant. Dexmedetomidine may be
able to attenuate the vasodilatory effect of maropitant during the injection since there is no
decrease in blood pressure during injection.
The mechanism of blood pressure reduction during maropitant administration remains
unclear, but may be associated with the formulation of injectable maropitant which contains
maropitant, sulfobutylether-beta-cyclodextrin, and metacresol [38]. Sulfobutylether-beta-
cyclodextrin is a cyclic oligosaccharide that acts as a carrier molecule for maropitant. Presently,
there is no evidence that the dose of cyclodextrin in injectable maropitant has a significant
effect on mean arterial pressure or heart rate with intravenous injection in anesthetized dogs
[39,40].
The preservative, metacresol, is a common excipient in insulin formulations for humans.
Currently, there is no literature that documents the blood pressure effects of metacresol injec-
tion in veterinary medicine. Reported side effects of metacresol in human medicine include
localized allergic skin reactions, l cytotoxicity to fibroblast cell, human adipocyte, and mono-
cytic cells [41–43]. Further investigation is needed to evaluate the effect of metacresol on blood
Fig 4. Heart rate (HR) of groups AwIBP, GaAB and GaDB. Values are expressed as mean ± SD. �Denotes value differs significantly (p�0.05) from
baseline value in AwIBP group. # Denotes value differs significantly (p�0.05) between AwIBP and GaAB groups. There was no significant change in
HR within the GaAB and GaDB groups compared to the baseline HR.
https://doi.org/10.1371/journal.pone.0229736.g004
The effect of intravenous maropitant on blood pressure in healthy awake and anesthetized dogs
PLOS ONE | https://doi.org/10.1371/journal.pone.0229736 February 27, 2020 9 / 15
pressure. Another formulation of injectable maropitant (Prevomax1, Dechra1) is available
which does not contain metacresol. This formulation is marketed in Europe for veterinary use
and is currently not available in the United States. In the European formulation, the excipient
contains benzyl alcohol, betadex sulfobutyl ether sodium, citric acid anhydrous and sodium
hydroxide [44]. There is currently no information regarding the effects of IV administration of
this formulation on blood pressure and future studies are warranted.
Neurokinin receptors are associated with blood pressure regulation [45,46]. Neurokinin-1
agonists can cause centrally mediated vasoconstriction or peripheral vasodilation. The NK-1
agonist, SP, activates tachykinin NK-1 receptors on the vascular endothelium to cause release
of endothelial nitric oxide promoting vascular smooth muscle relaxation [47]. Spinal cord and
intracerebroventricular activation of NK-1 receptors by substance P in rats evokes a vasopres-
sor and positive chronotropic response, peripheral activation caused a vasodilatory effect
[45,48]. Studies in dogs have found that SP has vasodilatory effects on hepatic arterial and por-
tal vascular beds [49].
In human clinical trials, both aprepitant and fosaprepitant, which are NK-1 antagonists
used for oral/intranasal and IV administration, respectively, are reported to be associated with
a decrease in blood pressure or the occurrence of hypotension [50–53]. Maropitant may inter-
act with NK-1 receptors centrally and peripherally causing transient decreases of blood pres-
sure and a reflex chronotropic response in dogs as we observed in this study.
Arterial blood pressure is regulated by the autonomic nervous system, renin angiotensin
system, and the arginine vasopressin pressor systems in dogs [54,55]. The significant increase
in HR observed in the awake dogs may have been due to activation of the autonomic nervous
system to compensate for the decrease in blood pressure during maropitant injection. The
underlying mechanism is unknown but may be associated with modulation of the cardiovas-
cular system and sympathetic system by central NK-1 receptors [56].
The non-invasive blood pressure measurement method was unable to detect the effect of
blood pressure changes over time. Non-invasive blood pressure measurement in awake
patients requires a minimum of three to five consecutive values and the values also need to
have less than 20% variability to be considered accurate [57,58]. Our data was collected with
less than 20% variability and the readings were taken at 5 minutes intervals. Oscillometric
blood pressure was unable to identify real-time pressure changes that were detected with inva-
sive blood pressure measurement. Blood pressure changes caused by maropitant during intra-
venous administration potentially may not be observable with oscillometric methods of blood
pressure monitoring due to these limitations.
Results of this study only hold true for the drug doses that were used in this study. Drug
doses were chosen based on doses used for premedication on canine anesthesia patients at this
institution. At our institution, 0.005 mg kg-1 acepromazine is a standard dose when adminis-
tered concurrently with an opioid analgesic drug such as butorphanol. The choice of drug
doses for dexmedetomidine and butorphanol falls within published dosing ranges [59]. The
acepromazine dose that was used in this study was lower than the referenced dosing range
[59]. A published retrospective study cited a clinical dosing of 0.005 to 0.07 mg kg-1 of acepro-
mazine for preanesthetic medication or tranquilization [60]. Published label drug doses are
for administration of the single agent. Multi-modal premedication dictates that when using
multiple drugs, the dose of each individual drug is decreased in order to take advantage of the
desired attributes of each drug but limit the unwanted side effects of each drug.
The goal of subcutaneous lidocaine injection prior to intravenous and intraarterial catheter
placement was to decrease discomfort and pain associated with catheterization. Pain from
local anesthetic injections primarily occurs with needle insertion and infiltration of the drug
[61]. To minimize injection pain associated with lidocaine, subcutaneous injection of lidocaine
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with 30-gauge needle was used. Smaller needle size and subcutaneous injection instead of
intradermal injection have proven to decrease injection pain with local anesthetic [61,62]. In
awake dogs, response to pain, such as vocalization or increased heart rate and blood pressure,
was absent during lidocaine injection for catheter placement. The effect of administration of
lidocaine for catheter placement was assumed to be minimal.
One limitation of this study was that a control group with dogs anesthetized with only iso-
flurane without premedication was not included. Previous studies have already suggested that
a decrease in blood pressure was associated with IV maropitant injection in dogs anesthetized
with inhalant anesthesia without premedication [10,14]. Not including such a control group
was due to considerations for laboratory animal welfare. Administration of appropriate pre-
medication prior to inhalant anesthesia minimizes patient discomfort and stress and also
reflects recommendations put forth by the American Animal Hospital Association (AAHA)
guidelines for anesthesia [63]. Lack of blinding of the observer was another limitation. Since
recording of the data in this study was an objective value rather than a subjective value, the
influence of non-blinding on data recording is assumed to be minimal.
An additional limitation was that cardiac output was not measured precluding differentia-
tion of cardiac output changes versus systemic vascular resistance as responsible for the blood
pressure changes associated with maropitant administration. We also did not measure invasive
blood pressure and non-invasive blood pressure concurrently in each group. This was due to
the inability to collect all five necessary consecutive readings within two minutes due to the
natural limitations of the oscillometric blood pressure device used in the study. The oscillo-
metric device we used will take more than 2 minutes to cycle for five blood pressure readings.
We did not investigate the excipients of the maropitant formulation. We cannot isolate the
effects of maropitant from that of the carrier formulation. However, current literature in
humans suggests that blood pressure changes occur with different formulations of NK-1 antag-
onists, indicating that the blood pressure effects observed are most likely associated with the
NK-1 antagonist themselves and not the excipient. Lastly, healthy research beagles with intact
cardiovascular responses were used in this study, therefore, results may not be extrapolated to
critically ill patients or patients with cardiovascular compromise.
Conclusion
Intravenous administration of maropitant is associated with a transient decrease in blood
pressure in awake dogs with a concomitant increase in HR. Clinically significant hypotension
occurred in dogs premedicated with acepromazine, induced with propofol, and maintained
on isoflurane. Dogs premedicated with dexmedetomidine did not experienced a significant
decrease in blood pressure associated with IV maropitant administration during isoflurane
anesthesia. Maropitant should be administered slowly when given IV and blood pressure and
heart rate should be monitored during and after administration, especially in anesthetized
dogs receiving acepromazine premedication.
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